NASDAQ:FOLD Amicus Therapeutics Q2 2025 Earnings Report $6.06 -0.22 (-3.50%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$6.09 +0.03 (+0.50%) As of 07/25/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Amicus Therapeutics EPS ResultsActual EPSN/AConsensus EPS $0.01Beat/MissN/AOne Year Ago EPSN/AAmicus Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$146.68 millionBeat/MissN/AYoY Revenue GrowthN/AAmicus Therapeutics Announcement DetailsQuarterQ2 2025Date7/31/2025TimeBefore Market OpensConference Call DateThursday, July 31, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Amicus Therapeutics Earnings HeadlinesMorgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline ExpansionJuly 25 at 11:19 PM | msn.comDimerix Secures Major Licensing Deal with Amicus TherapeuticsJuly 24 at 7:43 PM | tipranks.comTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trillion U.S. manufacturing boom. Dubbed Trump’s “New Golden Age” tech, this breakthrough has drawn praise from Elon Musk and NVIDIA’s CEO—and early investors may have a rare chance to get in ahead of the crowd.July 26 at 2:00 AM | Brownstone Research (Ad)Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025July 21, 2025 | globenewswire.comAmicus gains as Morgan Stanley upgrades on Aurobindo case and Pom-Op switchingJuly 18, 2025 | msn.comAmicus (FOLD) Gets Japan Approval for Pombiliti + OpfoldaJuly 16, 2025 | finance.yahoo.comSee More Amicus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amicus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amicus Therapeutics and other key companies, straight to your email. Email Address About Amicus TherapeuticsAmicus Therapeutics (NASDAQ:FOLD), a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.View Amicus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings?Why Freeport-McMoRan Stock May Hit a New High After Earnings BeatMicrosoft’s AI Bet Faces a Major Test This Earnings SeasonAmazon Stock Rally Hits New Highs: Buy Into Earnings?TSLA Earnings Week: Can Tesla Break Through $350?Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your Portfolio Upcoming Earnings Cadence Design Systems (7/28/2025)Enterprise Products Partners (7/28/2025)Welltower (7/28/2025)Waste Management (7/28/2025)Starbucks (7/29/2025)PayPal (7/29/2025)AstraZeneca (7/29/2025)Mondelez International (7/29/2025)Booking (7/29/2025)America Movil (7/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
